JP2009539984A5 - - Google Patents

Download PDF

Info

Publication number
JP2009539984A5
JP2009539984A5 JP2009515443A JP2009515443A JP2009539984A5 JP 2009539984 A5 JP2009539984 A5 JP 2009539984A5 JP 2009515443 A JP2009515443 A JP 2009515443A JP 2009515443 A JP2009515443 A JP 2009515443A JP 2009539984 A5 JP2009539984 A5 JP 2009539984A5
Authority
JP
Japan
Prior art keywords
pharmaceutical composition
pharmaceutically acceptable
carboxamide
dihydro
chloro
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2009515443A
Other languages
English (en)
Japanese (ja)
Other versions
JP5226678B2 (ja
JP2009539984A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2007/013721 external-priority patent/WO2007146248A2/en
Publication of JP2009539984A publication Critical patent/JP2009539984A/ja
Publication of JP2009539984A5 publication Critical patent/JP2009539984A5/ja
Application granted granted Critical
Publication of JP5226678B2 publication Critical patent/JP5226678B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2009515443A 2006-06-12 2007-06-12 安定性ラキニモド製剤 Expired - Fee Related JP5226678B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US81324706P 2006-06-12 2006-06-12
US60/813,247 2006-06-12
PCT/US2007/013721 WO2007146248A2 (en) 2006-06-12 2007-06-12 Stable laquinimod preparations

Publications (3)

Publication Number Publication Date
JP2009539984A JP2009539984A (ja) 2009-11-19
JP2009539984A5 true JP2009539984A5 (enExample) 2012-03-08
JP5226678B2 JP5226678B2 (ja) 2013-07-03

Family

ID=38832466

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2009515443A Expired - Fee Related JP5226678B2 (ja) 2006-06-12 2007-06-12 安定性ラキニモド製剤

Country Status (27)

Country Link
US (3) US7989473B2 (enExample)
EP (1) EP2035001B1 (enExample)
JP (1) JP5226678B2 (enExample)
KR (4) KR20160013273A (enExample)
CN (1) CN101466379B (enExample)
AR (1) AR061348A1 (enExample)
AT (1) ATE532515T1 (enExample)
AU (1) AU2007258366B2 (enExample)
BR (1) BRPI0713694A2 (enExample)
CA (2) CA2899472C (enExample)
CY (1) CY1113003T1 (enExample)
DK (1) DK2035001T3 (enExample)
EA (1) EA018031B1 (enExample)
ES (1) ES2377149T3 (enExample)
HR (1) HRP20120093T1 (enExample)
IL (1) IL195724A (enExample)
MX (1) MX2008015808A (enExample)
NO (1) NO342485B1 (enExample)
NZ (1) NZ573846A (enExample)
PL (1) PL2035001T3 (enExample)
PT (1) PT2035001E (enExample)
RS (1) RS52169B (enExample)
SI (1) SI2035001T1 (enExample)
TW (1) TWI400073B (enExample)
UA (1) UA96449C2 (enExample)
WO (1) WO2007146248A2 (enExample)
ZA (1) ZA200810790B (enExample)

Families Citing this family (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8314124B2 (en) 2004-02-06 2012-11-20 Active Biotech Ab Crystalline salts of quinoline compounds and methods for preparing them
HRP20141160T1 (hr) 2005-10-19 2015-01-16 Teva Pharmaceutical Industries Ltd. Kristali natrijevog lakvinimoda i postupak za njihovu proizvodnju
ES2377149T3 (es) 2006-06-12 2012-03-22 Teva Pharmaceutical Industries Limited Preparaciones de laquinimod estables
SI2234485T1 (sl) 2007-12-20 2014-03-31 Teva Pharmaceutical Industries Ltd. Stabilni lakvinimodni pripravki
KR20110048571A (ko) * 2008-09-03 2011-05-11 테바 파마슈티컬 인더스트리즈 리미티드 면역 기능을 지닌 ２―옥소―１,２―다이하이드로―퀴놀린 조절제
DE102010048788A1 (de) 2009-02-13 2011-05-19 Amw Gmbh Transdermales System mit Immunmodulator
DE102009008851A1 (de) 2009-02-13 2010-08-19 Amw Gmbh Transdermales System mit Immunmodulator
PT2442651E (pt) * 2009-06-19 2015-10-22 Teva Pharma Tratamento da esclerose múltipla com laquinimod
AU2010276748A1 (en) * 2009-07-30 2012-03-15 Teva Pharmaceutical Industries Ltd. Treatment of Crohn's disease with laquinimod
HUE029983T2 (en) 2009-08-10 2017-04-28 Teva Pharma Treatment of BDNF-related diseases with laquinimod
DE102010026879A1 (de) 2010-02-11 2011-08-11 AMW GmbH, 83627 Transdermales System mit Immunmodulator
US8501766B2 (en) * 2010-03-03 2013-08-06 Teva Pharmaceutical Industries Ltd. Treatment of rheumatoid arthritis with a combination of laquinimod and methotrexate
KR20130006640A (ko) * 2010-03-03 2013-01-17 테바 파마슈티컬 인더스트리즈 리미티드 라퀴니모드를 이용한 루푸스 신장염의 치료
KR20130036217A (ko) * 2010-03-03 2013-04-11 테바 파마슈티컬 인더스트리즈 리미티드 라퀴니모드를 이용한 루푸스 관절염의 치료
MX2013000333A (es) 2010-07-09 2013-02-26 Teva Pharma N-etil-n-fenil-1,2-dihidro-4-hidroxi-5-cloro-1-metil-2-oxoquinoli na-3-carboxamida deuterada, sales y usos de la misma.
WO2012006544A1 (en) 2010-07-09 2012-01-12 Teva Pharmaceutical Industries Ltd. 5-chloro-4-hydroxy-1-methyl-2-oxo-n-phenyl-1,2-dihydroquinoline-3-carboxamide, salts and uses thereof
EP2648732A4 (en) * 2010-12-07 2014-04-30 Teva Pharma USE OF LAQUINIMOD TO REDUCE TEMPERATURE, IMPROVE FUNCTIONAL STATUS AND IMPROVE LIFE QUALITY IN PATIENTS WITH MULTIPLE SCLEROSIS
US20130028866A1 (en) * 2011-07-28 2013-01-31 Yossi Gilgun Treatment of multiple sclerosis with combination of laquinimod and interferon-beta
CN103781354A (zh) * 2011-07-28 2014-05-07 泰华制药工业有限公司 用拉喹莫德与醋酸格拉替雷的组合治疗多发性硬化症
JP2014530821A (ja) * 2011-10-12 2014-11-20 テバ ファーマシューティカル インダストリーズ リミティド ラキニモドおよびフィンゴリモドを組み合わせた多発性硬化症の治療
JP2015505564A (ja) 2012-02-03 2015-02-23 テバ ファーマシューティカル インダストリーズ リミティド 第一選択の抗ＴＮＥα療法に失敗したクローン病患者を治療するためのラキニモドの使用
EP3225617A1 (en) 2012-02-16 2017-10-04 Teva Pharmaceutical Industries Ltd N-ethyl-n-phenyl-1,2-dihydro-4,5-di-hydroxy-1-methyl-2-oxo-3-quinoline carboxamide, preparation and uses thereof
US20130259856A1 (en) 2012-03-27 2013-10-03 Teva Pharmaceutical Industries, Ltd. Treatment of multiple sclerosis with combination of laquinimod and dimethyl fumarate
TW201350467A (zh) 2012-05-08 2013-12-16 Teva Pharma Ｎ－乙基－４－羥基－１－甲基－５－（甲基（２，３，４，５，６－五羥基己基）胺基）－２－側氧－ｎ－苯基－１，２－二氫喹啉－３－甲醯胺
TW201400117A (zh) 2012-06-05 2014-01-01 Teva Pharma 使用拉喹莫德治療眼發炎疾病
US20130345257A1 (en) * 2012-06-26 2013-12-26 The Regents Of The University Of California Composition for lupus nephritis and methods of making and using the same
AR091706A1 (es) * 2012-07-11 2015-02-25 Teva Pharma Formulaciones de laquinimod sin agentes alcalinizantes
TW201410243A (zh) * 2012-08-13 2014-03-16 Teva Pharma 用於治療大麻素受體型１（ｃｂ１）媒介之疾病之拉喹莫德（ｌａｑｕｉｎｉｍｏｄ）
TW201410244A (zh) * 2012-08-13 2014-03-16 Teva Pharma 用於治療ｇａｂａ媒介之疾病之拉喹莫德（ｌａｑｕｉｎｉｍｏｄ）
EA201590788A1 (ru) * 2012-11-07 2015-12-30 Тева Фармасьютикал Индастриз Лтд. Аминные соли лахинимода
HK1218254A1 (zh) * 2013-02-15 2017-02-10 Teva Pharmaceutical Industries Ltd. 用拉喹莫德治疗多发性硬化症
MX2015010967A (es) 2013-03-14 2015-10-26 Teva Pharma Formulaciones transdermicas de laquinimod.
HK1220444A1 (zh) * 2013-03-14 2017-05-05 Teva Pharmaceutical Industries Ltd. 拉喹莫德钠晶体和用於制造它们的改进方法
MX2016003763A (es) * 2013-09-27 2016-10-28 Teva Pharma Terapia de combinacion con laquinimod para tratamiento de esclerosis multiple.
TW201609098A (zh) * 2013-12-20 2016-03-16 泰瓦藥品工業有限公司 拉喹莫德（ｌａｑｕｉｎｉｍｏｄ）於延緩亨丁頓舞蹈症進展的用途
EP3094330A4 (en) * 2014-01-17 2017-09-27 Teva Pharmaceutical Industries Ltd Treatment of crohn's disease using low doses of laquinimod
EA201692180A1 (ru) 2014-04-29 2017-08-31 Тева Фармасьютикал Индастриз Лтд. Лахинимод для лечения пациентов с рецидивирующе-ремиттирующим рассеянным склерозом (рррс) с высоким статусом инвалидизации
CN110193014B (zh) * 2019-06-06 2021-05-11 温州医科大学 一种注射用拉喹莫德胶束冻干制剂及制备方法、拉喹莫德注射制剂

Family Cites Families (48)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3024257A (en) * 1961-04-10 1962-03-06 Frosst & Co Charles E Stable preparations of alkali metal salts of estrone sulfate
FR2340735A1 (fr) * 1976-02-11 1977-09-09 Roussel Uclaf Nouveaux derives de l'acide 3-quinoleine carboxylique, leur procede de preparation et leur application comme medicament
IE52670B1 (en) * 1981-03-03 1988-01-20 Leo Ab Heterocyclic carboxamides,compositions containing such compounds,and processes for their preparation
DE3437232A1 (de) * 1984-10-10 1986-04-17 Mack Chem Pharm Stabilisierte injektionsloesungen von piroxicam
SE8902076D0 (sv) 1989-06-09 1989-06-09 Pharmacia Ab Derivatives of quinoline-3-carboxanilide
HUT60458A (en) 1991-02-01 1992-09-28 Sandoz Ag Process for producing benzyloxyphenyl derivatives and pharmaceutical compositions comprising same
US5540934A (en) * 1994-06-22 1996-07-30 Touitou; Elka Compositions for applying active substances to or through the skin
CH687615A5 (de) * 1994-09-07 1997-01-15 R W Johnson Pharmaceutical Res Tropen-Verpackung.
US5912349A (en) * 1997-01-31 1999-06-15 Pharmacia & Upjohn Company Process for the preparation of roquinimex
US20030124187A1 (en) * 1997-02-14 2003-07-03 Smithkline Beecham Laboratoires Pharmaceutiques, Pharmaceutical formulations comprising amoxycillin and clavulanate
SE9801474D0 (sv) 1998-04-27 1998-04-27 Active Biotech Ab Quinoline Derivatives
US6077851A (en) * 1998-04-27 2000-06-20 Active Biotech Ab Quinoline derivatives
SE9802550D0 (sv) 1998-07-15 1998-07-15 Active Biotech Ab Quinoline derivatives
US6133285A (en) * 1998-07-15 2000-10-17 Active Biotech Ab Quinoline derivatives
SE9802549D0 (sv) 1998-07-15 1998-07-15 Active Biotech Ab Quinoline derivatives
US6121287A (en) * 1998-07-15 2000-09-19 Active Biotech Ab Quinoline derivatives
EP1616562A1 (en) 1999-06-07 2006-01-18 ALTANA Pharma AG Novel preparation and administration form comprising an acid-labile active compound
RS51019B (sr) * 1999-10-25 2010-10-31 Active Biotech Ab. Lekovi za lečenje malignih tumora
SE0002320D0 (sv) 1999-10-25 2000-06-21 Active Biotech Ab Malignant tumors
JP2002031610A (ja) 2000-07-14 2002-01-31 Ajinomoto Co Inc 生体分子複合体の界面残基を同定する方法
US6307050B1 (en) * 2000-08-29 2001-10-23 R. T. Alamo Venture I Llc Method of synthesizing flosequinan from 4-fluoroanthranilic acid
US6802422B2 (en) * 2000-12-12 2004-10-12 Multi-Comp, Inc. Sealed blister assembly
US6706733B2 (en) 2001-05-08 2004-03-16 Dainippon Ink And Chemicals, Inc. Quinolinone derivative formulation and its production method
US20030119826A1 (en) * 2001-09-24 2003-06-26 Pharmacia Corporation Neuroprotective treatment methods using selective iNOS inhibitors
SE0201778D0 (sv) * 2002-06-12 2002-06-12 Active Biotech Ab Process for the manufacture of quinoline derivatives
US6875869B2 (en) * 2002-06-12 2005-04-05 Active Biotech Ab Process for the manufacture of quinoline derivatives
US7560557B2 (en) * 2002-06-12 2009-07-14 Active Biotech Ag Process for the manufacture of quinoline derivatives
US8980870B2 (en) * 2002-09-24 2015-03-17 Boehringer Ingelheim International Gmbh Solid telmisartan pharmaceutical formulations
US7820145B2 (en) * 2003-08-04 2010-10-26 Foamix Ltd. Oleaginous pharmaceutical and cosmetic foam
US7790197B2 (en) * 2003-06-09 2010-09-07 Warner-Lambert Company Llc Pharmaceutical compositions of atorvastatin
US20050271717A1 (en) * 2003-06-12 2005-12-08 Alfred Berchielli Pharmaceutical compositions of atorvastatin
US20040253305A1 (en) * 2003-06-12 2004-12-16 Luner Paul E. Pharmaceutical compositions of atorvastatin
US20060188568A1 (en) * 2003-10-30 2006-08-24 Lupin Limited Stable formulations of ace inhibitors and methods for preparation thereof
SE0400235D0 (sv) * 2004-02-06 2004-02-06 Active Biotech Ab New composition containing quinoline compounds
US8314124B2 (en) * 2004-02-06 2012-11-20 Active Biotech Ab Crystalline salts of quinoline compounds and methods for preparing them
HRP20141160T1 (hr) 2005-10-19 2015-01-16 Teva Pharmaceutical Industries Ltd. Kristali natrijevog lakvinimoda i postupak za njihovu proizvodnju
ES2377149T3 (es) 2006-06-12 2012-03-22 Teva Pharmaceutical Industries Limited Preparaciones de laquinimod estables
US20080087929A1 (en) * 2006-10-11 2008-04-17 Infineon Technologies Ag Static random access memory with thin oxide capacitor
SI2234485T1 (sl) 2007-12-20 2014-03-31 Teva Pharmaceutical Industries Ltd. Stabilni lakvinimodni pripravki
KR20110048571A (ko) 2008-09-03 2011-05-11 테바 파마슈티컬 인더스트리즈 리미티드 면역 기능을 지닌 ２―옥소―１,２―다이하이드로―퀴놀린 조절제
PT2442651E (pt) 2009-06-19 2015-10-22 Teva Pharma Tratamento da esclerose múltipla com laquinimod
AU2010276748A1 (en) 2009-07-30 2012-03-15 Teva Pharmaceutical Industries Ltd. Treatment of Crohn's disease with laquinimod
HUE029983T2 (en) 2009-08-10 2017-04-28 Teva Pharma Treatment of BDNF-related diseases with laquinimod
KR20130036217A (ko) 2010-03-03 2013-04-11 테바 파마슈티컬 인더스트리즈 리미티드 라퀴니모드를 이용한 루푸스 관절염의 치료
KR20130006640A (ko) 2010-03-03 2013-01-17 테바 파마슈티컬 인더스트리즈 리미티드 라퀴니모드를 이용한 루푸스 신장염의 치료
US8501766B2 (en) 2010-03-03 2013-08-06 Teva Pharmaceutical Industries Ltd. Treatment of rheumatoid arthritis with a combination of laquinimod and methotrexate
WO2012006544A1 (en) 2010-07-09 2012-01-12 Teva Pharmaceutical Industries Ltd. 5-chloro-4-hydroxy-1-methyl-2-oxo-n-phenyl-1,2-dihydroquinoline-3-carboxamide, salts and uses thereof
MX2013000333A (es) 2010-07-09 2013-02-26 Teva Pharma N-etil-n-fenil-1,2-dihidro-4-hidroxi-5-cloro-1-metil-2-oxoquinoli na-3-carboxamida deuterada, sales y usos de la misma.

Similar Documents

Publication Publication Date Title
JP2009539984A5 (enExample)
JP6228544B2 (ja) ニコチン含有治療用組成物のための賦形剤
JP5226678B2 (ja) 安定性ラキニモド製剤
JP2015515459A5 (enExample)
CN102892418A (zh) 含烟碱的药物组合物
WO2008144730A3 (en) Stable pharmaceutical formulation for a dpp-iv inhibitor
CN102933199A (zh) 含有烟碱的药物组合物
WO2012048846A3 (de) Phosphatbinderformulierung zur einfachen einnahme
JP2015533134A5 (enExample)
IL292465B1 (en) Neuroactive compounds and methods of using them
WO2009112274A3 (en) Inhalation composition containing aclidinium for treatment of asthma and chronic obstructive pulmonary disease
JP2014503593A5 (enExample)
JP2012503668A5 (enExample)
JP2015527321A5 (enExample)
CN101732342B (zh) 口服补液盐泡腾片及其应用
WO2008116601A3 (en) Solid dosage forms comprising aliskiren and pharmaceutically acceptable salts thereof
JP2018521007A5 (enExample)
TN2014000031A1 (en) Use of organic compound for the treatment of noonan syndrome
JP2008534522A5 (enExample)
WO2008111674A1 (ja) 口腔粘膜貼付ブプレノルフィン製剤の製造方法
JP2009508916A5 (enExample)
EA201170784A1 (ru) Гранулы тамсулозина для фиксированной комбинации
CA2565993A1 (en) Salt of 4-or 5- aminosalicylic acid
JP2015512948A5 (enExample)
JP2009073778A (ja) グルクロノラクトン含有固形製剤